Fig. 6: Synergistic drug combinations to kill B02/TPT-resistant RB.
From: Functional genomics identifies new synergistic therapies for retinoblastoma
a WERI-RB1 were treated with increasing concentrations of B02 (top), TPT (middle), or Navitoclax (Nav, bottom), and with vehicle (black), or with EC50 doses of TPT (blue, two-drug combos), B02 (red, two-drug combos), or Nav (green, two-drug combos), or pairs of EC50 drugs (brown, three-drug combos), and cell number (a, left graphs) and apoptosis (a, right graphs) defined after 3 days (n = 2 ± range). b Representative PARP western used to quantify apoptosis in (a). The two-drug (c) or three-drug (d) combos from (a) are summarized in the tables, and CI vs. effect (Fa) graphed (gray areas and green lines as in Fig. 4a). e The indicated RB cell lines were transduced with control or p53-targeting sgRNA lentivirus, selected in puromycin, then 7 × 105 cells were seeded and treated as indicated. At 24 h, cell number (trypan blue) and apoptosis (PARP) were quantified (n = 3, mean ± SD, **p < 0.01, ***p < 0.001 ordinary one-way ANOVA, Tukey’s multiple comparisons test). Representative PARP, p53, and p21 western blots are shown.
